Short answer
Danaher Corporation (DHR) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only a non-filing disclaimer, not operating results or financial metrics.
Danaher Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only a non-filing disclaimer, not operating results or financial metrics
- No investor-actionable earnings information appears in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $6.0B, up 3.5%; core growth only 0.5%, indicating currency provided meaningful reported-sales support
- Adjusted EPS $2.06, up 9.5%; GAAP EPS $1.45 versus $1.32, supported by operating profit growth to $1.344B
- Biotechnology core sales rose 7.0%, while Diagnostics declined 4.0%; lighter Cepheid respiratory demand remains a key weakness
- Operating cash flow $1.322B and free cash flow $1.085B, reinforcing capacity for acquisitions and shareholder returns
- Full-year adjusted EPS guidance raised to $8.35-$8.55; excludes incremental financing interest for the anticipated Masimo acquisition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Danaher Corporation 8-K filings
Get the next DHR 8-K as it lands
Follow DHR for push alerts, or ask the research agent what this filing means.